Dopamine uptake sites and dopamine receptors in Parkinson's disease and schizophrenia.
Dopamine uptake sites, labelled by 3 nM [3H]GBR 12935, were reduced by 28-34% in post-mortem Parkinson's diseased striata (n = 22) compared to control striata (n = 28). There was no significant difference between post-mortem striata from schizophrenics (n = 16) and controls. Both dopamine D1 and D2 receptors are consistently elevated in Parkinson's diseased striata from patients who have not been medicated with L-dopa pre-mortem. Both these receptors are down-regulated by L-dopa pre-mortem. In schizophrenia, however, while the density of D1 receptors is similar to control, the D2 receptors are consistently elevated.
Pearce
R K
RK
Department of Pharmacology, University of Toronto, Canada.
Seeman
P
P
Jellinger
K
K
Tourtellotte
W W
WW
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D001665:Binding Sites; D004298:Dopamine / Q000493:pharmacokinetics*; D005260:Female; D006801:Humans; D007980:Levodopa / Q000627:therapeutic use; D008024:Ligands; D008297:Male; D008875:Middle Aged; D010300:Parkinson Disease / Q000188:drug therapy / Q000378:metabolism / Q000473:pathology*; D010879:Piperazines / Q000032:analysis; D011954:Receptors, Dopamine / Q000032:analysis*; D017447:Receptors, Dopamine D1; D017448:Receptors, Dopamine D2; D012559:Schizophrenia / Q000378:metabolism / Q000473:pathology*
D008024:Ligands; D010879:Piperazines; D011954:Receptors, Dopamine; D017447:Receptors, Dopamine D1; D017448:Receptors, Dopamine D2; D007980:Levodopa; C044630:1-(2 (diphenylmethoxy)ethyl)-4-(3-phenylpropyl)piperazine; D004298:Dopamine